50 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
the circumstances.
In preparing the interim condensed consolidated financial statements, the nature of significant judgments made by management in applying … by nature
Six Months Ended June 30,
RMB’000
Clinical trials related expenses
Employee benefit expenses (Note 6)
Consultancy fee
Office expenses
R&D
20-F
2021 FY
EX-4.11
CNTB
Connect Biopharma Holdings Ltd
31 Mar 22
Annual report (foreign)
4:33pm
. As an exempt salaried employee, you will be expected to work additional hours as required by the nature of your work assignments.
Your employment … or neglect continues for thirty (30) days following your receipt of written notice from the Board stating with specificity the nature of such failure
20-F
2021 FY
EX-4.10
CNTB
Connect Biopharma Holdings Ltd
31 Mar 22
Annual report (foreign)
4:33pm
p.m., Monday through Friday. As an exempt salaried employee, you will be expected to work additional hours as required by the nature of your work … stating with specificity the nature of such failure, refusal or neglect; provided, however, that prior to the determination that “Cause” under clauses
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
19 Nov 21
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
4:01pm
.
Hanauer SB. Advances in IBD. Gastroentrerology & Hepatology. 2016;12(11):704-707
Kobayahsi T, Siegmund B, Le Berre C, et al. Ulcerative Colitis. Nature Reviews: Disease Primers. 2020;6:74.
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
or omitted.
The unaudited interim condensed consolidated financial statements include adjustments of a normal recurring nature, as necessary … to be reasonable under the circumstances.
In preparing the interim condensed consolidated financial statements, the nature of significant judgments made
6-K
f33qwup
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
F-1
EX-10.12
dbfdz1p4z
26 Feb 21
Registration statement (foreign)
4:56pm
F-1/A
EX-3.2
y8klbmr92jkr8gb
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
20-F
EX-1.1
0f96ucnaih
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.13
5rboq8iiimgdy6h
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
ojbdm70qmnbhvcjfz
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
F-1
EX-3.1
irtq16dgqk94a
26 Feb 21
Registration statement (foreign)
4:56pm
DRS
EX-3.1
dm1acyzi9v1
17 Dec 20
Draft registration statement
12:00am
DRS
EX-10.1
sxhzqezrzkv
17 Dec 20
Draft registration statement
12:00am
F-1
EX-10.1
qm26to ckxi4
26 Feb 21
Registration statement (foreign)
4:56pm
6-K
EX-99.2
9bcji43
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
EX-99.2
y06t1fxi9d82mxrg
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
F-1
EX-10.14
5s5 18iubhwqurw
26 Feb 21
Registration statement (foreign)
4:56pm
F-3/A
47nnoey6rqo46zgcl
20 May 22
Shelf registration (foreign) (amended)
6:54pm
20-F
EX-2.5
dsc8m42q9s6rw
31 Mar 22
Annual report (foreign)
4:33pm